Cleanser Regulatory Labelling: EU, FDA & NMPA Cosmetic Rinse-Off Category Guide

Overview #

Regulatory labelling for rinse-off cleansers is not a paperwork exercise. It is the first filter that determines whether your product clears customs, passes retailer compliance review, and survives a consumer complaint. The EU, FDA, and NMPA each treat rinse-off products differently — not just in ingredient restrictions, but in how they define the product category itself, what claims trigger reclassification, and what your label must physically say. We work through all three frameworks on every cleanser brief we take, because a label that works in the US will get flagged in the EU, and a formula cleared for NMPA filing may need ingredient substitutions before it can ship to Germany.

How the Three Frameworks Actually Differ #

Most brand owners come to us thinking regulatory compliance is about ingredient lists. It is partly that. But the bigger issue is category definition — specifically, what your product claims to do and how that claim is read by each authority.

Under EU Cosmetics Regulation 1223/2009, a rinse-off cleanser is a cosmetic product as long as it does not claim therapeutic or physiological modification beyond cleansing, perfuming, and protecting. The moment your marketing copy says “reduces acne-causing bacteria by 99%” or “clinically treats seborrheic dermatitis,” you are in borderline medicinal product territory. We have seen brands lose their entire EU launch timeline — 6 to 9 months of delay — because a single claim on the outer carton triggered a medicinal product review in Germany.

The FDA Cosmetics Guidelines framework is more permissive on claims but stricter on specific actives. Rinse-off cleansers containing salicylic acid above 2% for acne, or zinc pyrithione above 1% for dandruff, are regulated as OTC drug-cosmetic combination products. That means an OTC monograph must apply, and your label must carry Drug Facts. We almost always push back when a brand asks for “2.5% salicylic acid face wash” — not because the formula is hard, but because the regulatory pathway adds 4 to 6 months and most indie brands are not prepared for it.

NMPA is the framework that surprises brands most. Under NMPA Cosmetic Regulation, rinse-off cleansers are classified as ordinary cosmetics, which means filing rather than registration — faster in theory. But NMPA maintains a Prohibited and Restricted Substances List that diverges from both EU and FDA in specific ways. Methylisothiazolinone (MIT) is restricted to 0.0015% in rinse-off products under EU Annex V. NMPA currently permits up to 0.01% in rinse-off. That sounds like more flexibility, but it creates a labelling bifurcation problem: you cannot run a single global formula at 0.008% MIT and label it identically in both markets.

The fragrance allergen disclosure row is where we see the most label rework. EU requires individual declaration of 26 fragrance allergens above 0.01% in rinse-off products. That threshold is under review — the SCCS Scientific Opinion on fragrance allergens has been pushing toward a lower threshold and an expanded allergen list for several years. Brands that lock in a fragrance blend today may need to reformulate within 18 to 24 months if the revision passes. We now require fragrance suppliers to provide full allergen profiling at 0.001% detection threshold on every new brief, specifically because of this.

Ingredient Restrictions That Actually Affect Cleanser Formulas #

This is where the regulatory frameworks stop being abstract and start costing money.

Preservative selection is the clearest example. MIT at 0.0015% in rinse-off is a real formulation constraint — that concentration is borderline effective against gram-negative organisms in a water-heavy surfactant base. We have had batches pass challenge testing at lab scale (500g, 25°C) and then show gram-negative contamination at week 8 of preservative efficacy testing at 200kg production scale. The difference was water activity and mixing shear. At production scale, the surfactant blend was not fully homogenized before the preservative was added, which created micro-pockets of unpreserved aqueous phase. We now hold a minimum 20-minute post-addition mixing cycle before any in-process sampling.

Phenoxyethanol is the default alternative, but EU limits it to 1.0% across all product types. At 1.0% in a rinse-off cleanser with a pH above 6.0, you are relying heavily on the rinse-off kinetics to carry microbial load away. That works in most cases. It does not work in a leave-on-adjacent format like a cleansing balm that sits on skin for 60 seconds before emulsification.

Zinc pyrithione is another one. Effective antidandruff active, well-understood mechanism, but EU restricted it to 1.0% in rinse-off hair products and prohibited it in rinse-off face products as of 2022. Brands that had a “clarifying face and scalp wash” SKU had to bifurcate their line or reformulate. We had three clients in that position simultaneously. Two reformulated to piroctone olamine at 1.0%. One discontinued the face application claim. Neither solution was cheap.

For brands targeting the Chinese market, the NMPA Cosmetic Regulation filing dossier requires a full ingredient safety assessment for any ingredient not on the IECIC (Inventory of Existing Cosmetic Ingredients in China). New ingredients require a separate new cosmetic ingredient registration, which takes 12 to 18 months. This catches brands using novel botanical extracts or newer peptide-based surfactants that have EU INCI status but no IECIC listing.

Consumer Perception Studies and Instrumental Measurement #

Here is where the article angle gets interesting — because most brands conflate regulatory compliance with efficacy substantiation, and they are not the same thing. Compliance gets your product to market. Efficacy data is what keeps it there.

For rinse-off cleansers, the instrumental methods we use most are sebumeter (sebum output, Courage + Khazaka SM 815), corneometer (skin hydration, post-wash), tewameter (TEWL, barrier integrity post-wash), and pH meter (skin surface pH recovery). The standard protocol we run is a 4-hour post-wash measurement window: baseline, immediately post-wash, 1 hour, 2 hours, 4 hours. That window captures the rebound curve — how fast the skin barrier recovers after surfactant exposure.

A cleanser that drops TEWL by 15% at 30 minutes post-wash but recovers to baseline by 2 hours is a very different product from one that shows persistent TEWL elevation at 4 hours. The second one is damaging the barrier. We have seen brands launch with the first measurement only — the 30-minute number looks great in a press release. By the time consumer complaints about dryness come in, the product is already in retail.

One study we reference internally: a double-blind, randomized controlled trial (n=42, 8 weeks, twice-daily wash protocol) comparing a sodium lauryl sulfate (SLS) base at 12% versus a sodium lauroyl methyl isethionate (SLMI) base at 14% in a matched pH 5.5 formula. Corneometer readings at week 4 showed 18% higher hydration retention in the SLMI group. TEWL at week 8 was 22% lower in the SLMI group. Consumer self-assessment scores for “skin feels tight after washing” were 34% lower in the SLMI group. The SLS formula was cheaper by $0.12 per unit at the raw material level. Most brands, when they see that data, choose the SLMI base. Some don’t.

Consumer panel study design for cleansers is something we get asked about constantly. The minimum viable panel for a claim like “gentle enough for sensitive skin” is 30 subjects with confirmed sensitive skin (ISAC score ≥2 or dermatologist-confirmed), 4-week minimum duration, twice-daily use, with both instrumental and self-assessment endpoints. Below 30 subjects, the variance in skin type response makes the data statistically weak. We have seen panels run at n=20 that produced beautiful-looking results — and then failed to replicate in a second panel. Honestly, that is a waste of everyone’s time and money.

Before/after photography protocol is underspecified in most briefs we receive. The variables that matter: standardized lighting (cross-polarized and parallel-polarized, minimum), fixed camera distance (we use 30cm for face, 15cm for body), consistent time of day (morning, pre-wash baseline), and a minimum 48-hour washout period before baseline photography. Without washout, you are photographing the residual effect of whatever the subject used the night before. We rejected the first photography vendor on one project because they could not guarantee consistent color temperature across sessions. That sounds pedantic. It is not — color temperature shifts make pore appearance and skin tone look different even when nothing has changed.

Designing a 12-Week Cleanser Efficacy Study #

This is usually where projects go sideways, because brands want to design the study after the formula is finalized. We push to design the study protocol at the same time as the formula brief. The endpoints you want to claim drive the formula decisions, not the other way around.

For a 12-week rinse-off cleanser study, here is the structure we recommend:

Study population: 40 to 50 subjects (allows for 15–20% dropout and still hit n=35 for statistical power at 80%, two-tailed, α=0.05). Stratify by Fitzpatrick skin type — at minimum, ensure you have representation across types II through V if you are making any claim about skin tone or brightening.

Wash protocol: twice daily, morning and evening, with a standardized water temperature (32–34°C) and wash duration (30 seconds). This sounds over-specified. It is necessary. Water temperature alone changes surfactant rinse-off kinetics enough to affect TEWL readings.

Measurement timepoints: baseline (day 0), week 2, week 4, week 8, week 12. Week 2 is the early signal — if you are seeing barrier disruption at week 2, you need to know before week 12. Week 8 is where most meaningful efficacy differences become statistically significant for hydration and sebum endpoints.

Instrumental endpoints: corneometer (hydration), sebumeter (sebum), tewameter (TEWL), mexameter (melanin index if brightening claim), pH meter (skin surface pH). Run all five at every timepoint. The cost of adding an endpoint at week 8 because you forgot it at baseline is a full study restart.

Consumer self-assessment: validated questionnaire, minimum 10 items, Likert scale 1–7. Include both positive attributes (“skin feels comfortable after washing”) and negative attributes (“skin feels tight,” “skin feels dry”). The negative items are where you find the real signal. Brands always want to report the positive scores. We always look at the negative ones first.

Photography: cross-polarized and parallel-polarized at each timepoint, same protocol as above. If you are making a pore or texture claim, add VISIA or Antera 3D imaging at baseline, week 4, and week 12.

Regulatory substantiation: if you intend to use this data for EU claims substantiation, the study must comply with ISO Standards for cosmetic efficacy testing — specifically ISO 24444 (sun protection) is not relevant here, but ISO 29621 and the broader ISO/TC 217 framework for cosmetic testing methods applies. The study report needs to be authored or co-signed by a qualified assessor. A study run by your marketing team with a consumer panel company does not meet this bar.

For brands developing barrier-repair or sensitive skin cleansers, the 12-week protocol above is the minimum we recommend before making any “clinically tested” or “dermatologist tested” claim. For acne and blemish control cleansers, you need to add a lesion count endpoint (IGA scale or direct comedone/papule count) and extend to 16 weeks minimum for meaningful acne data.

One thing we are still not fully convinced about: the correlation between in-vitro surfactant mildness assays (zein solubilization, RBC hemolysis) and actual in-vivo TEWL outcomes. The supplier data and our clinical results do not always agree. We use the in-vitro data as a screening tool, not a claim basis.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask on every cleanser brief, because the answers determine everything from preservative selection to label architecture.

If you are launching in the EU first, we start with the fragrance allergen audit before we finalize the formula. If you are going into China, we check IECIC status on every non-standard ingredient before we even run a pilot batch. If you are targeting the US mass market with an acne claim, we have a direct conversation about OTC monograph requirements before the brief goes to the lab.

For a typical rinse-off face cleanser targeting sensitive skin across EU and US markets, our standard starting point is a SLMI or sodium cocoyl isethionate (SCI) surfactant base at 10–14% active, pH 5.0–5.5, phenoxyethanol at 0.8–1.0%, and a minimal fragrance load below 0.5% with full allergen profiling. That formula clears EU Annex restrictions, stays below FDA OTC thresholds, and gives us a clean NMPA filing path if needed.

Airless pump packaging adds $0.40–$0.80 per unit at MOQ 1,000 — most indie brands cannot absorb that on a cleanser SKU where retail price pressure is real. We usually recommend standard disc-top or flip-cap for cleansers unless there is a specific oxidation-sensitive active that requires it.

The 12-week study design above is not optional if you want defensible claims. We can help you scope it, but we cannot run it for you — that needs an independent CRO for the data to be credible.

Frequently Asked Questions #

Q: Our formula has 0.003% MIT — is that going to be a problem for EU?

Yes. EU Annex V limits MIT to 0.0015% in rinse-off products. At 0.003% you are 2× over the limit. We would need to either reduce MIT to 0.0015% and boost with a co-preservative, or switch to a different preservative system entirely. This is a reformulation, not a label fix.

Q: We want to say “dermatologist tested” on pack — what does that actually require?

At minimum, a patch test or RIPT (Repeat Insult Patch Test) with dermatologist oversight, n=50 subjects, with zero sensitization reactions. “Dermatologist tested” does not require efficacy data — it requires a safety test conducted or supervised by a licensed dermatologist. The study report needs to be on file. EU and NMPA both expect to see it in the safety dossier.

Q: Can we use the same label for EU and US?

Not if you have fragrance allergens above 0.01% — EU requires individual declaration, FDA does not. You will also need a Responsible Person named on the EU label, which has no FDA equivalent. In practice, most brands run separate label versions. We design the formula to be compliant in both markets, but the label artwork is always market-specific.

Q: We want to claim “reduces pores by 30%” — is that achievable in 12 weeks?

Pore size claims are tricky. A 30% reduction in pore appearance (as measured by VISIA or Antera imaging) is achievable with the right formula — typically a combination of salicylic acid at 1.5–2.0% and a sebum-absorbing agent. But “reduces pores” as a permanent structural claim is not supportable. The claim needs to be “visibly reduces the appearance of pores” and the study needs to show the effect at the end of the wash protocol, not 4 hours later when sebum has re-accumulated.

Q: How long does NMPA filing take for a rinse-off cleanser?

For an ordinary cosmetic with all IECIC-listed ingredients, the filing review is typically 3 to 5 months from submission. If you have any ingredient not on the IECIC, add 12 to 18 months for new ingredient registration. The dossier preparation itself — safety data, formula disclosure, manufacturing site documentation — takes us 6 to 8 weeks to compile if all supplier data is in hand.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.